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The p.N478D missense mutation in human mitochondrial poly(A) polymerase (mtPAP) has previously been
implicated in a form of spastic ataxia with optic atrophy. In this study, we have investigated fibroblast cell
lines established from family members. The homozygous mutation resulted in the loss of polyadenylation of
allmitochondrial transcripts assessed; however, oligoadenylationwas retained. Interestingly, thishaddifferen-
tialeffectsontranscriptstability thatweredependenton theparticularspeciesof transcript.Thesechangeswere
accompanied by a severe loss of oxidative phosphorylation complexes I and IV, and perturbation of de novo
mitochondrial protein synthesis. Decreases in transcript polyadenylation and in respiratory chain complexes
were effectively rescued by overexpression of wild-type mtPAP. Both mutated and wild-type mtPAP localized
to themitochondrial RNA-processinggranules thereby eliminatingmislocalization as a cause of defective poly-
adenylation. In vitro polyadenylation assays revealed severely compromised activity by the mutated protein,
which generated only short oligo(A) extensions on RNA substrates, irrespective of RNA secondary structure.
The addition of LRPPRC/SLIRP, a mitochondrial RNA-binding complex, enhanced activity of the wild-type
mtPAP resulting in increased overall tail length. The LRPPRC/SLIRP effect although present was less marked
with mutated mtPAP, independent of RNA secondary structure. We conclude that (i) the polymerase activity
of mtPAP can be modulated by the presence of LRPPRC/SLIRP, (ii) N478D mtPAP mutation decreases
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polymeraseactivity and (iii) thealteration inpoly(A) length issufficient tocausedysregulationofpost-transcrip-
tional expression and the pathogenic lack of respiratory chain complexes.
INTRODUCTION
The human mitochondrial genome, mtDNA, encodes 13 poly-
peptides, all of which are essential for the coupling of cell
respiration to ATP production (1). These proteins arise from
the intra-mitochondrial translation of mt-mRNAs processed
from large polycistronic precursors, which are mostly matured
by the addition of short (50 nt) poly(A) tails (2,3). Adenylation
is necessary to complete the termination codon of seven open-
reading frames, but the rationale for why human mt-mRNAs
are poly- rather than oligo-adenylated remains unclear.
Although polyadenylation of transcripts has been almost univer-
sally maintained in cells and organelles, its function varies dra-
matically (4,5). For example, in the eukaryotic cytosol, the
polyadenylation of mRNA permits association with poly(A)-
binding protein (PABP) family members, leading to an increase
in mRNA stability (6,7). Further, the presence of a poly(A) tail
and PABPs allows interactions with factors that bind to the 5′
methylguanylate cap structure of mRNAs thereby stimulating
translation initiation (8). Conversely, polyadenylation of RNA
in various eubacteria can promote degradation and regulate
quality control of more stable tRNA or rRNA (9). Furthermore,
variations in polyadenylate function are also apparent between
organelles. Yeast lack a mitochondrial poly(A) polymerase
(mtPAP), and no mitochondrial mRNA carries a 3′ post-
transcriptional extension (4,10), whereas polyadenylation of
plant and algal organellar RNA follows the eubacterial pattern
and stimulates decay (11,12). Trypanosome mitochondria are
yet more complicated. Short (15–20 nt) oligo(A) tails are
added to pre- or fully edited RNA and are necessary to
promote stability, whereas longer U/A extensions of 200–300
nt designate the mRNA as ready for translation (13). It has
long been known that human mt-mRNA can be polyadenylated
(3), but even after numerous attempts to determine its exact role,
the function of this modification is still unclear. A number of dif-
ferent approaches by various groups have been used to address
this question. These include siRNA-mediated depletion of tran-
scripts encoded by the PAPD1 gene, now termed MTPAP in the
new nomenclature (14–16), occlusion or degradation of poly(A)
tails by targeting cytosolic PABP or poly(A) nuclease to the
mitochondrion (17), and overexpression of the mitochondrial
deadenylase PDE12 (18). In each case, mt-mRNAs were ana-
lysed and different effects on stability were observed, dependent
on the transcript analysed.
All these methods, however, introduced some level of artifi-
cial genetic manipulation, each of which can be prone to artefact
and consequently difficulties in interpretation of resulting data.
In contrast, we were invited by an Old Order Amish family to in-
vestigate the cause of a profound form of spastic ataxia with optic
atrophy in a subset of family members. Samples from these
patients indicated that their clinical condition resulted from a
homozygous p.N478D missense mutation in the MTPAP gene
(19). Our initial studies of mRNA transcripts obtained from
family blood samples were able to confirm that the mutation
caused a loss of polyadenylation in the mt-mRNA species ana-
lysed. More recently, using fibroblast cell lines from affected
as well as unaffected family members, we have been able to
undertake more in-depth analysis into the consequences of
non-polyadenylation of mt-mRNAs.
RESULTS
The p.N478D mtPAP mutation causes a defect in oxidative
phosphorylation
Our initial investigations were limited to the analysis of blood
samples from members of a large Old Order Amish family
with multiple children suffering from a progressive and auto-
somal recessive neurodegenerative disorder. Genomic analysis
revealed a candidate pathogenic mutation in MTPAP, the gene
encoding mtPAP. We therefore performed mitochondrial
poly(A) tail assays of representative mitochondrially encoded
transcripts from whole blood. These confirmed an mt-mRNA
polyadenylation defect associated with the c.1432A.G
(p.N478D) mutation in clinically affected members, but no
further studies were possible at that time (19). Here, we
present investigations on skin fibroblast cell lines from three
family members, two affected individuals homozygous for the
mutation (P1 and P2) and one unaffected heterozygote sibling
(Het). Initially, it was important to confirm that the polyadenyla-
tion defect was recapitulated in the cultured fibroblasts. RNA
was isolated, and four mt-mRNAs were subjected to the mito-
chondrial poly(A) tail length assays as described previously
(20). For each mt-mRNA analysed, a lack of polyadenylation
was apparent in the pathogenic homozygote lines (P1 and P2),
concomitant with an increase in oligoadenylated species
(Fig. 1A lanes 2 and 3). The heterozygote behaved similarly to
the control line, although there was evidence of a mild increase
in oligoadenylated mRNA (Fig. 1A lane 1 cf lane 4). Homopoly-
meric oligoadenylation was confirmed by sequence analysis of
MPAT-derived species for MTCO1 (data not shown). We then
assessed whether the marked loss of polyadenylation caused
any phenotypic consequences. Cell growth rate was examined
first, using either glucose- or galactose-based media. Galactose
is a carbon source that forces cells to use oxidative phosphoryl-
ation (OXPHOS). The growth defect seen in the homozygote
mutant lines was more pronounced on this substrate than on
glucose (Supplementary Material, Fig. S1). Cell lysates from
the two patient cell lines, the unaffected sibling (Het) and one un-
related control (C) were then prepared and subjected to western
blot (Fig. 1B). No observable difference in the steady-state levels
of mtPAP could be detected, showing the p.N478D mutation did
not affect the stability of the protein. In contrast, in the homozy-
gote p.N478D lines, a substantial decrease was apparent in the
mitochondrially encoded proteins of the respiratory chain,
ND1, a component of complex I and COX1–3, members of
complex IV. NDUFB8, although nuclear encoded, was also
present at decreased steady-state levels as it is sensitive to
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complex I assembly. As expected, no decrease in complex II
(SDHA) was observed consistent with all its components
being nuclear encoded. Analysis of the fully assembled
OXPHOS complexes by blue native gels (Fig. 1C) reflected
the severe decrease seen in components of complexes I and IV,
and this was further mirrored in the enzymatic activities
(Fig. 1D). Intriguingly, complexes III and V appeared unaffect-
ed. Taken together, these data are consistent with a selective
defect of mitochondrial gene expression.
To confirm that the mtPAP p.N478D mutation was respon-
sible both for the loss of mt-mRNA polyadenylation and the con-
sequent reduction in complexes I and IV, we designed a lentiviral
vector to express wild-type mtPAP constitutively. Following
transduction and selection of the four cell lines (P1, P2, Het
and C), lysates and RNA were prepared. Expression of wild-type
mtPAP (+LVMTPAP) in the homozygote mutant cell lines was
sufficient to restore steady-state levels of mtDNA gene products
at both the mRNA and protein level (Supplementary Material,
Fig. S2A and B). Further, analysis of various mt-mRNAs
showed a restoration of poly(A) tail for lines P1 and P2
(RNA14, Fig. 1 lanes 2, 3 cf 6, 7;MTND3, Supplementary Mater-
ial, Fig. S2C lanes 2, 3 cf 6, 7). In all four cell lines transduced
with wild-type mtPAP, the final tail length exhibited a slightly
increased median length compared with the untransduced con-
trols (lanes 1, 4 cf 5–8 for both RNA14 in Fig. 1A and MTND3
in Supplementary Material, Fig. S2C).
Figure 1. The MTPAP 1432A.G mutation causes defective mt-mRNA polyadenylation and a respiratory chain deficiency. (A) RNA was isolated from patient
(P1 and P2) and control (Het, unaffected heterozygote; C, unrelated control) fibroblasts before (lanes 1–4) or after (lanes 5–8) transduction with a wild-type
MTPAP transgene (+LVMTPAP). The length of the mRNA poly(A) tail was assessed by MPAT in the four transcripts indicated. Representative gels depict
fluorescently-labelled products separated through a 10% denaturing polyacrylamide gel and visualized by laser scanning. Zero extension (A0) is the position of
migration predicted post-3′ processing of the transcript prior to any addition. A50 indicates the position of a poly(A) of 50 nt. Densitometric profiles of the signal
from the RNA14 MPAT are presented in the far right panel. (B) Cell lysates (40 mg) isolated from patient and control fibroblasts were separated via 12% denaturing
SDS–PAGE, and immunoblotting was performed. The images are representative of data using antibodies targeting mtPAP and OXPHOS subunits (listed in materials
and methods). Detection was by ECL+ and Biorad ChemiDoc MP imaging system. (C) Mitochondria (40 mg) isolated from patient and control fibroblasts were ana-
lysed by Blue Native PAGE (4.5–16%). Each of the OXPHOS complexes was decorated using primary antibodies targeted to NDUFA9 (CI), Core 2 subunit (CIII),
a-subunit (CV), the holoenzyme (CIV) and SDHA (CII). Sizes of the detected complexes are indicated to the left of panels, and the complex identities are shown on the
right. (D) The activities of OXPHOS complexes I, IV and V were determined in mitochondria isolated from patient (black) and control (white) fibroblasts. Activities
are expressed as nmol rotenone-sensitive NADH oxidized/min/mg mt-protein (CI), nmol reduced cytochrome c oxidized/min/mg mt-protein (CIV) and NADH oxi-
dized/min/mg mt-protein (CV). N ¼ 4, errors bars indicate +SD. Student t-test (ns ∗P, 0.05; ∗∗P , 0.01; ∗∗∗P , 0.001).
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Aberrant mtPAP induces significant effects on the
steady-state levels and translation of mitochondrial mRNA
species
Depletion of mtPAP, mediated by siRNAs targeting theMTPAP
transcript, has been shown by several groups to result in
transcript-specific effects on the steady-state levels of
mt-mRNAs in cultured human cell lines (14–16). In the homo-
zygote patient lines (Fig. 2A lanes 2 and 3), we also saw
transcript-specific effects, where steady-state levels of RNA14
and all MTCO were decreased, MTND1 increased and MTND3
unaffected. A similar trend had been noted when mt-transcripts
lacked polyadenylated termini as a consequence of the poly(A)
tails being removed by a cytosolic poly(A)-specific ribonuclease
that had been targeted to mitochondria (17). To determine what
effect these altered steady-state levels, caused by the mutant
mtPAP, had on the translation of these transcripts, de novometa-
bolic labelling was performed. Autoradiographic data analysis
of the homozygote compared with the control indicated that
there were varied but reproducible differences in the amount
of translation products from different transcripts (Fig. 2B).
There was an evident decrease in de novo synthesis of the com-
ponents of the COX2/3 ATP6 triplet, which was in contrast to the
increase in ND5 and ND2. Those transcripts that showed
decreased stability, such as MTCO3, showed a concomitant
decrease in translation product. However, there was no consist-
ent correlation between transcript level and translation as the
dramatic increase in stability of MTND1 (Fig. 2A) did not
result in a concomitant increase in ND1 (Fig. 2B).
Mutant and wild-type mtPAP are found in mitochondrial
RNA granules
It has been shown previously that mitochondrial RNA is pro-
cessed in distinct foci referred to as mitochondrial RNA granules
(MRGs) (22). We posited that the maturation of mitochondrial
mRNA may also occur in MRGs. Consequently, we performed
immunocytochemistry to detect mtPAP (endogenous, Fig. 3A)
and a marker for the MRGs, namely GRSF-1. As shown in
Figure 3A, both antibodies revealed discrete co-localizing foci
within the mitochondrial network, demonstrating that mtPAP
is indeed present in MRGs. Repeat experiments with FLAG-
tagged wild-type mtPAP (Fig. 3B) also showed this punctate dis-
tribution. We then wished to determine whether the p.N478D
mutation led to any loss of mtPAP localization. As seen in
Figure 3C, the p.N478D mtPAP also showed a similar pattern
of co-localization, consistent with the mutant being present in
MRGs.
Activity of the p.N478D-mutant mtPAP is severely
compromised
The p.N478D mtPAP mutation did not affect either the stability
or the location of the enzyme necessitating further investigations
to characterize the effect of this mutation on mtPAP. The crystal
structure of this non-canonical poly(A) polymerase has been
solved (23) revealing that the protein dimerises but lacks a
classic RNA-binding domain. The region encompassing
p.N478, however, was disordered in the crystal. To determine
whether the p.N478 mutation influences the dimer formation,
we overexpressed and purified both the wild-type and mutant
enzyme for use in in vitro studies. Both wild-type and mutant
mtPAP were isolated to electrophoretic purity and subjected to
gel filtration analysis. As shown in Supplementary Material,
Fig. S3, both mutant and wild-type mtPAP form dimers indicat-
ing that the p.N478D mutation does not affect the overall fold or
the oligomeric state of the protein. The mutation, therefore, must
affect mtPAP function directly, because the N478 region does
not contribute to the dimer interface (23). We subsequently com-
pared polyadenylation activities of the two enzymes in vitro. Ini-
tially, we generated long RNA substrates [terminal 277 nt of
MTND3 or 248 nt of RNA14, with or without oligo(A8)]. The
wild-type enzyme extended from both templates irrespective
of the oligoadenylation status. The mutant protein, however,
was unable to discernibly extend unadenylated MTND3 sub-
strate (Fig. 4A). Using such a large substrate under these electro-
phoresis conditions, however, meant that it was not possible to
determine whether p.N478D was entirely inactive or only able
to oligoadenylate, as could be seen for mt-mRNA in the
mutant cell lines (Fig. 1A). The absence of any activity would
suggest that another poly(A) polymerase would have to be
present to add the oligo(A) modification. We therefore designed
a number of short (40 nt) RNA substrates to mimic either internal
sections of MTCO1 and MTND3 or the native 3′ end of RNA14
post-processing. The latter substrate was synthesized with
Figure 2.The p.N478D mutation in mtPAP affects steady-state levels and trans-
latability of mtDNA-encoded transcripts. (A) RNA was isolated from control and
patient fibroblasts, and steady-state levels of mitochondrial rRNA and mRNA
were assessed by northern blotting (4 mg), using the probes indicated. A probe
against the 18S rRNA transcript was used as a loading control. The blot is repre-
sentative of data from three independent RNA isolations. (B) De novo protein
synthesis of mitochondrially encoded proteins was analysed in control and
patient fibroblasts. Cells were incubated with [35S]-methionine/cysteine for 1 h
in the presence of the cytosolic translation inhibitor emetine dihydrochloride
(100 mg/ml). Equal amounts of whole cell lysate (50 mg) were separated via
15–20% denaturing SDS–PAGE and translation products visualized by auto-
radiography. Individual polypeptides were designated by their mobility (21).
The protein profiles are representative of data derived from three independent
experiments.
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or without an oligo(A8) 3′ terminal extension to establish
whether mtPAP had a different preference for (i) correctly pro-
cessed 3′ termini compared with any free 3′ end and (ii) to see
whether mtPAP only used pre-oligoadenylated transcripts as a
template. Saturating levels of wild-type mtPAP were able to
extend 40 nt from the 3′ terminus of both the internal
MTND3 sequences (Supplementary Material, Fig. S4) and also
correctly processed RNA14 with or without oligo(A8) ends
(Fig. 4B lanes 2 and 6). Thus, the wild-type mtPAP demonstrated
no preference for 3′ terminal sequence of the RNA substrate. In
addition to the main population of extended products, there was
a second, much longer population. The ratio of this product
(Fig. 4C lane 6, ∗) to the main product varied between
experiments. In contrast, the mutant mtPAP showed severely
Figure 3. Both wild-type and mutant mtPAP co-localize with mitochondrial RNA granules. (A) HeLa cells expressing an HA-tagged version of GRSF1 isoform 1
(GRSF1) were immunolabelled with anti-HA and anti-mtPAP (endogenous) antibodies and then analysed by confocal microscopy. Images were merged to determine
co-localization. (B) HeLacells transfected toexpress both HA-taggedGRSF1-HA anda C-terminal FLAG-tagged wild-typemtPAPwere immunolabelledusing anti-HA
andanti-FLAG antibodiesandanalysedbyconfocal microscopy. Images were merged todetermineco-localization. (C)Similar confocalanalysis was performedonHeLa
cells transfected to express GRSF1-HA and the p.N478D mutant version of mtPAP-FLAG. Immunolabelling and image analysis was as described in (B).
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compromised activity, where the extension achieved on either
template, with or without oligo(A8), was only 5–10 nt
(RNA14 shown in Fig. 4B lanes 3 and 7). The mutant protein
was not able to generate longer extensions even in prolonged
-h incubations. To determine whether the p.N478D mutation
affected polymerase processivity, it was first necessary to iden-
tify whether mtPAP was distributive or processive under these
in vitro conditions. The extension assay was therefore performed
under conditions where the enzyme/RNA substrate ratio fell
below 1 : 1. Figure 4C shows that the wild-type enzyme does
not fully extend the subset of RNA substrate to which it has
bound, indicating that under these in vitro conditions, it is
distributive, thus precluding any effect of the mutation on
enzyme processivity.
LRPPRC and LRPPRC/SLIRP enhance poly(A) tail
length extension
Leucine-rich pentatricopeptide repeat-containing protein
(LRPPRC) binds mature or unprocessed mitochondrial mRNA
in vivo (24,25) and is often found associated with another
much smaller RNA-binding protein, SLIRP (SRA stem loop
interacting RNA-binding protein) (26). When the gene encoding
LRPPRC or its homologue was deleted in mice or Drosophila,
the resulting mt-mRNAs were found at low steady-state level,
with reduced poly(A) tail lengths, and in many cases were aber-
rantly translated (27,28). Further, a recent study concluded that
LRPPRC promoted mtPAP-mediated polyadenylation, possibly
by resolving secondary structures at the 3′ termini of RNA sub-
strates, facilitating access of mtPAP to unstructured 3′ ends (25).
We therefore examined whether the presence of LRPPRC or the
LRPPRC/SLIRP complex affected poly(A) extension by wild-
type or mutant mtPAP. In the presence of wild-type mtPAP
and LRPPRC (0.5 or 1.25 mM) poly(A) tail length was increased
by a mean value of 12 nt (Fig. 5A cf lanes 2 and 3, 5 and 6).
However, the extension was more pronounced on addition of
the LRPPRC/SLIRP complex (Fig. 5A lane 4 cf lane 2),
whereas SLIRP alone had only a minimal effect on mtPAP activ-
ity (data not shown). Assays were performed for 1 h, but increas-
ing extension time to 2 h had only a minimal effect on maximal
Figure 4. In vitro polyadenylation activity of mtPAP. (A) Polyadenylation activity of recombinant wild-type (WT; lanes 2–4) and mutant (p.N478D; lanes 6–8)
mitochondrial poly(A) polymerase (0.55 mM) was determined with increasing ATP concentrations. The RNA substrate was an unadenylated 277-nt 3′ fragment of
MTND3 (0.25 mM). The right hand panel contains an IVT RNA artefact (500 nt) present in the absence of mtPAP (lane 5). Reactions were quenched with 90% for-
mamide/1× TBE, separated through a 6% polyacrylamide/8.3 M urea gel, then stained with SYBR gold and visualized by scanning with a Typhoon FLA 9500 instru-
ment. (B) Short RNAs (0.25 mM) corresponding to the final 40 nucleotides ofRNA14with (A8, lanes 5–8) or without (A0, lanes 1–4) an oligo(A8) addition were used
as templates for polyadenylation by recombinant wild-type (WT; lanes 2 and 6) or mutant (p.N478D; lanes 3 and 7) mtPAP (0.55 mM). An equal amount of BSA was
added in a parallel experiment as a control (lanes 4 and 8). Products were separated through 15% polyacrylamide/8.3 M urea gel and visualized as in (A). (C) Increasing
amounts of wild-type mtPAP (34 nM to 0.55 mM) were added to the short RNA14A0 (0.25 mM) template in the presence (lanes 8–12) or absence (lanes 2–6) of
LRPRRC/SLIRP complex. A higher molecular species (∗) of varying intensity was observed with wild-type mtPAP. Products were separated and visualized as in (B).
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tail length (Supplementary Material, Fig. S4). Interestingly, a
similar modulation of extension by LRPPRC/SLIRP was noted
on an RNA substrate carrying eight adenylates (A8) residues at
the 3′ terminus (Fig. 5B) precluding the increase in extension
being due to LRPPRC/SLIRP resolving 3′ terminal structure.
Assays performed with the p.N478D-mutant mtPAP together
with the LRPPRC/SLIRP complex also resulted in a further,
minor, extension of only 15–20 nt (Fig. 5C lanes 4 and 5), in
comparison with an additional extension of 50 nt with wild-
type mtPAP in the presence of complex (Fig. 5C cf lanes 2 and
3). Intriguingly, the longer population illustrated in Figure 4C
lane 6 was in all cases resolved upon the addition of LRPPRC/
SLIRP (Fig. 4C lane 12).
DISCUSSION
The p.N478D mutation in mtPAP causes a severe progressive
neurodegenerative disorder in all homozygous patients identi-
fied. The resultant cellular defect was identical in both of the
patient cell lines analysed and manifested as a profound loss of
mitochondrial OXPHOS complexes I and IV. Why such select-
ivity ? The mtPAP mutation caused selective variability in the
stability of mt-mRNAs presumably due to their lack of polyade-
nylation. There have been several previous studies into the
effects of deadenylation on mt-mRNA stability in human cul-
tured cell lines, by using siRNA depletion of mtPAP in human
cell lines (14–16), overexpression of a mitochondrial deadeny-
lase PDE12 (18), or by the removal of poly(A) tails by targeting
the poly(A)-specific ribonuclease PARN to mitochondria (17).
A consensus pattern of stability now appears to be emerging.
The lack of a poly(A) tail appears to result in significant and
transcript-specific effects on mt-mRNA stability—MTND1,
MTND2 increased; MTCO transcripts decreased; MTND3,
MTND5, MTCYB mildly or unaffected. A similar trend was
noted for the patient homozygote cell lines, albeit that RNA14
was less stable than controls. These effects on transcript stability
are clear, and yet, there is no credible hypothesis to explain the
transcript-specific variability. What is the effect of this variabil-
ity on translation? Several recent publications have suggested a
link between the polyadenylation status of mt-mRNA and trans-
lation (8,17,18). It has been known for many years that transla-
tion in the eukaryotic cytosol can be stimulated by the
presence of a poly(A) tail by a mechanism promoted through
interaction between protein complexes at the 5′ methylguanylate
cap and the 3′ tail of the transcript (8). However, mitochondrial
mRNA species do not possess a 5′ cap structure or any known
5′ associating complexes (29,30). Artificial deadenylation
studies reported dramatic effects on mitochondrial protein
synthesis, but these data were complicated by the forced deade-
nylation causing either the loss of termination codons in open-
reading frames (17) or loss of the small mitoribosomal subunit
itself (18). Both of these effects would be expected to decrease
de novo protein synthesis.
None of the earlier studies assessed the effects of siRNA-
induced mtPAP depletion on mitochondrial protein synthesis,
although Nagaike et al. (15) did report marked effects on respir-
ation, consistent with a lack of OXPHOS complexes. Our current
studies show that de novo mitochondrial protein synthesis was
perturbed in the p.N478D mtPAP homozygote cell lines, with
certain species being increased (ND5), some decreased
(COX1–3) and many unaffected (e.g. ND1–3), and OXPHOS
was severely compromised. There was a degree of correlation
between effects on mt-mRNA stability and translation, as seen
for complex IV subunits, but others did not correlate well (e.g.
ND1 and ND5). In other relevant studies, knockout of
LRPPRC in mouse cardiac tissue and skeletal muscle resulted
in the decreased stability of all mitochondrial transcripts
except for the sole L-strand encoded product, MTND6 (28).
The remaining pool of transcripts retained only oligo(A) tails,
and translation was markedly affected. Although de novo syn-
thesis of most species was decreased as predicted from the
Figure 5. The LRPPRC/SLIRP complex modulates the polyadenylation activity of both wild-type and mutant mtPAP. (A) Polyadenylation activity was analysed
using wild-type mtPAP (0.55 mM) incubated for 1h with the short RNA14A0 substrate (0.25 mM), alone (lane 2), with LRPPRC (0.5 mM lane 3; 1.25 mM lane 6),
LRPPRC/SLIRP complex (0.5 mM, lane 4) or BSA (0.5 mM, lane 5). Products were separated and visualized as described earlier. (B) The effect of LRPPRC/
SLIRP complex (0.48 mM) on polyadenylation by wild-type mtPAP (0.55 mM) of an unadenylated (A0, lanes 2 and 3) compared with an oligoadenylated (A8,
lanes 5 and 6) RNA14 substrate was analysed. Products were separated and visualized as described earlier. (C) The effect of LRPPRC/SLIRP complex (0.48 mM;
lanes 3 and 5) on polyadenylation by p.N478D mutant (0.55 mM; lanes 4–5) poly(A) polymerase was compared with wild-type (0.55 mM; lanes 2–3) enzyme.
The short unadenylated RNA14A0 substrate (0.25 mM) was used. Products were separated and visualized as described earlier.
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effect on transcript stability, one translation product was in sub-
stantial excess. Following deletion in the fly of BSF, the homo-
logue of LRPPRC, the initial pattern of severely compromised
polyadenylation and steady-state levels of mt-mRNA was appar-
ent and similar to the mouse model (27). However, the fly dele-
tion differed as the transcript showed an additional problem of
aberrant processing, and a marked increase in translation was
noted, along with the production of novel translation products.
This would argue that at least in flies, polyadenylation of
mt-mRNA is not a prerequisite for translation. Finally, in
human cultured cell lines under conditions where poly(A) tails
were masked by mislocalization to the mitochondrion of the
major cellular poly(A)-binding protein, PABPC1, a decrease
in translation of all mt-mRNAs was seen (17). So, how does
the loss of the poly(A) tail on human mt-mRNA result in such
profound defects in assembly and stability of OXPHOS com-
plexes? Taken together with several of the studies referenced
earlier, it is clear that even relatively mild perturbations in de
novo synthesis of mitochondrially encoded proteins can have
major consequences for the assembly of OXPHOS complexes,
possibly reflecting the intricate process of integrating the
various subunits that are synthesized in different subcellular
locations. However, this still does not explain the molecular
basis of why the absence of the 3′ maturation event of polyade-
nylation could cause a modulation in protein synthesis that initi-
ates at the other end of the molecule. Many groups contributed to
resolving how polyadenylation functioned in the cytosol of
eukaryotes to stimulate translation. Research in human mito-
chondria has the disadvantages of not being able to transfect
the organelle with reporter constructs or to have a faithful in
vitro system for analysing protein synthesis (31,32). It has there-
fore taken numerous groups, many years and many experimental
approaches to try and understand the exact role of polyadenyla-
tion in the mammalian mitochondrion, and despite these efforts,
we are not yet in a position to fully explain this observation.
What is the consequence of the p.N478D mutation in human
mtPAP? We have shown that the mutated enzyme was correctly
dimerized and folded and could function in extending 3′ termini,
although the extension lengths were severely curtailed, indicat-
ing that the mutation caused a defect in but not a total loss of poly-
adenylation activity. This may explain the retention of short
oligo(A) tails on mt-mRNAs in the homozygous patient cell
lines. The mutation is located in the highly conserved fingers
domain of mtPAP (23). In the absence of any classical RNA-
binding domain in this non-canonical polymerase, it has been
suggested that the interface of this fingers domain with the
palm region may function in substrate binding, although the
exact RNA-binding domain is unclear (5). Alternatively,
another enzyme/complex may act in tandem with mtPAP to
facilitate either 3′ end binding or processivity as both wild-type
and mutant mtPAP act distributively in our in vitro assays, irre-
spective of LRPPRC/SLIRP addition. The hypothesis that there
are more, as yet unidentified, binding partners is particularly
appealing, given the poor activity of even the wild-type
mtPAP when assayed, in vitro. We have been exploring the pos-
sibility that a co-factor is necessary for optimal mt-PAP activity,
but our preliminary co-immunoprecipitation assays were unable
to identify any candidates to date. Recently, however, a similar
co-IP approach was used to identify two associating compo-
nents, the RNA helicase Suv3p and the RNA-degrading
enzyme, PNPase (33). The authors of this intriguing paper
supply further evidence to suggest that a transient complex of
these three proteins function in vivo to regulate the poly(A) tail
lengths of human mt-mRNAs dependent on the ratio of inorganic
phosphate to ATP in the mitochondrion.
Finally, how does the interplay between mtPAP and LRPPRC/
SLIRP impinge on polyadenylation? It has previously been
reported that on its own in vitro, mtPAP was unable to extend
3′ termini beyond short oligo(A) additions and required the pres-
ence of LRPPRC to promote extension (25). The authors of that
study performed several experiments to show that LRPPRC pro-
moted polyadenylation in vitro, suggesting that the complex
acted by resolving double-stranded regions to reveal single-
stranded RNA 3′ termini. We found some similarities to this im-
pressive work, but our data differed in several respects. First, we
found that mtPAP alone was able to extend from 3′ termini to
produce poly(A) tails. Second, although we were able to show
a consistent increase on the length of 3′ extension by the addition
of the LRPPRC, the extension was markedly enhanced when
LRPPRC was complexed with SLIRP. Third, we observed a con-
sistent LRPPRC/SLIRP-mediated increase in poly(A) tail length
even in the absence of 3′ secondary structure, arguing that the
role of the complex cannot only be to resolve secondary struc-
ture. Absolute extension varied mildly with the different buffer
conditions tested, but in all cases, the trends remained identical.
This promotion of extension is intriguing. In addition to the
extension of the major poly(A) species, a longer population of
varying proportion (Fig. 4C lane 6) was lost on addition of the
LRPPRC alone or complexed with SLIRP (Fig. 4C lane 12).
The presence of LRPPRC/SLIRP therefore appeared to act as
a molecular ruler. This interplay is reminiscent of a tripartite re-
lationship that regulates poly(A) extension in the eukaryotic
nucleus. The cleavage and polyadenylation-specific factor
CPSF binds to RNA elements close to mRNA 3′ termini and
stimulates poly(A) polymerase-mediated polyadenylation by
interacting with the nuclear poly(A)-binding protein PABPN1
that coats the nascent poly(A) tail (34). When the tail reaches
250 nt, PABPN1 then acts to disrupt the interaction with
CPSF, curtailing further extension. Although this similarity is
interesting, it cannot be an exact model for mtPAP. PABPN1
breaks the processivity exhibited by nuclear PAP, and we have
been unable to demonstrate processivity of mtPAP in vitro.
In summary, we have shown that the p.N478D mutation in
mtPAP is pathogenic. The defect prevents the enzyme from effi-
ciently polyadenylating mt-mRNA. The resultant loss of polya-
denylation causes a differential modulation of steady-state levels
of specific mt-mRNAs and perturbs mitochondrial protein syn-
thesis leading to profound depletion of complexes I and IV of
the respiratory chain, resulting in a form of spastic ataxia and
optic atrophy.
MATERIALS ANDMETHODS
Cell culture and viral vectors
Primary human dermal fibroblasts were established from indivi-
duals either heterozygous or homozygous for the 1432A.G mu-
tation in the MTPAP gene. Cell lines were immortalized by
retroviral expression of the HPV-16 E6E7 gene. Cells were cul-
tured in reagents purchased from Gibco Life Technologies;
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DMEM supplemented with 10% heat-inactivated foetal bovine
serum, 50 U/ml penicillin, 50 mg/ml streptomycin and 50 mg/ml
uridine (5% CO2 at 378C). Wild-type expression of MTPAP
was achieved by transduction with lentiviral particles (Geneco-
poeia) conferring puromycin resistance.
Mitochondrial poly(A) tail assay
The (20) technique was modified to use AlexaFluorw 647-
labelled gene-specific nested forward primers instead of radiola-
belled primers in the second round of PCR. The resulting PCR
products were separated on a 10% polyacrylamide/8.3 M urea
gel and directly imaged using a Typhoon FLA 9500 instrument
(GE/Fujifilm).
Metabolic labelling of mitochondrial translation
Essentially as described in (35) with a modification of a 1-h in-
cubation with radiolabel, protein aliquots (50 mg) were sepa-
rated by 15–20% (w/v) gradient SDS–PAGE. Radiochemical
signal was detected (Typhoon FLA 9500 instrument GE/Fuji-
film) and proteins identified by comparing their migration
patterns against established data (21).
RNA extraction and northern blotting
RNA was prepared by TRIZOL (Invitrogen) extraction follow-
ing manufacturer’s recommendations. Northerns were per-
formed as described (36) and signals quantified by scanning
with Typhoon FLA 9500 instrument (GE/Fujifilm).
MTPAP cloning, and purification of wild type
and p.N478D mtPAP
Human MTPAP (corresponding to residues 44–538) was sub-
cloned into the pET28a vector (Novagen) generating an
N-terminal 6× His fusion tag. The p.N478D mutant was
created with the QuikChange kit (Stratagene). Overexpression
of wild-type and p.N478D mtPAP in Escherichia coli BL21
Rosetta (DE3) cells (Novagen) was induced by overnight incu-
bation with 0.5 mM IPTG (Melford) at 208C. The soluble
protein was eluted from nickel affinity gel (Sigma) with 50 mM
Tris, pH 8.5, 300 mM NaCl and 250 mM imidazole, further puri-
fied by size exclusion chromatography and then concentrated in
a buffer containing 50 mM Tris, pH 8.5, 300 mM NaCl and 5%
(v/v) glycerol.
Cloning and purification of LRPPRC and LRPPRC/SLIRP
Codon-optimized (DNA 2.0) DNA constructs corresponding to
the mature form of human LRPPRC and amino acid 18–109 of
SLIRP were cloned in a pCDFDuet-1 vector (Novagen) for
co-expression. In addition, LRPPRC was cloned in pJexpress
401 (DNA 2.0). In both constructs, LRPPRC contains a TEV-
cleavable 6× His fusion tag at the N-terminus. LRPPRC and
LRPPRC/SLIRP were expressed and purified as previously
described for the MTERF4-NSUN4 complex (37).
Low resolution polyadenylation assay
RNA substrates were in vitro transcribed using the MAXIscriptw
SP6 Kit (Ambion) to generate 248- and 277-nt transcripts
mapping to the 3′ ends of MTATP6 and MTND3, respectively.
Polyadenylation reactions, product separation and visualization
were performed as described for high-resolution assays.
High-resolution polyadenylation assay
Single-stranded RNA mapping to the 3′ 40 nt of RNA14, with
and without oligo(A8) tails, were purchased from Dharmacon.
Polyadenylation reactions were carried out in 15 ml volume
composed of 50-ng RNA substrate, 50 mM Tris, pH 8.0, 40 mM
KCl, 1 mM DTT, 0.1 mM ATP, 10 mM MgCl2, 0.1 mM MnCl2
and 0.5 U/ml SUPERaseIn RNase inhibitor (Invitrogen). Wild-
type mtPAP, p.N478D mtPAP, LRPPRC/SLIRP complex or
LRPPRC was added at 0.5 mM each and incubated at 378C for
1 h unless stated. RNA products were fractionated on 15%
polyacrylamide/8.3 M urea gels, stained with SYBR Gold
(Invitrogen) and imaged with a Typhoon FLA 9500 instrument
(GE/Fujifilm).
Analysis of proteins by immunoblot and BN-PAGE
Proteins were separated by standard SDS–PAGE and then immo-
bilized on PVDF membrane (Immobilon-P, Millipore) by wet
transfer (100 V, 1 h at 48C) in Towbin buffer. Membranes were
blotted withprimary antibodies followed by HRP-conjugatedsec-
ondary antibodies (Dako) and visualized by ECL Prime (GE
Healthcare). One-dimension blue native gel electrophoresis
(4.5–16% w:v) was performed as described in (38) with 40 mg
of protein loaded per lane. Primary antibodies were from MitoS-
ciences COX1 (MS404), COX2 (MS405), COX3 (MS406),
SDHA (MS204), NDUFA9 (MS111), NDUFB8 (MS105),
Complex V a-subunit (MS502), Complex III core 2 (MS304);
Santa Cruz ATP8 (sc-84231), TOM20 (sc-17764), LRPPRC
(sc-66844); mtPAP (GeneTex GTX70156); COX holoenzyme
(gift from L. Nijtmans), ND1 (gift from A. Lombes).
OXPHOS activity assays
The activities of individual respiratory chain complexes were
determined in isolated mitochondria as previously described
for complex I and IV (39) and for complex V (40).
Immunofluorescence microscopy
HeLa cells were plated on coverslips and transiently transfected
with a HA-tagged version of GRSF1 isoform 1 (GRSF1-HA),
and FLAG-tagged wild-type or p.N478D mtPAP. Immunolabel-
ling with polyclonal anti-HA, monoclonal anti-mtPAP or mono-
clonal anti-FLAG was as described (22). Imaging was performed
using a Zeiss LSM700 confocal microscope.
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